CATALAYER NEWS
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa - Krystal Biotech, Inc
Source: Krystal Biotech, Inc · 2023-05-19
Full article text is available in the Catalayer news terminal.
RELATED ON CATALAYER
RELATED MARKETS
Prediction Markets